| HOME >> MEDICINE >> TECHNOLOGY |
Table 12: Drug Targets without any Identified Assigned Pathways 453
Table 13: Pathway Profiles According to BioCarta of Breast Cancer Drug Targets 455
Table 14: Pathway Profiles According to KEGG of Breast Cancer Drug Targets 481
Table 15: Pathway Profiles According to NetPath of Breast Cancer Drug Targets 512
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 523
Table 17: Top Competitive Target Strategies of Breast Cancer Drugs 524
Table 18: New and Unique Target Strategies of Marketed Breast Cancer Drugs 526
Table 19: The Competition Through Close Mechanistic Approximation Between Breast Cancer Drugs Being Marketed 527
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Breast Cancer Drugs 528
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Breast Cancer Drugs 529
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Breast Cancer Drugs 530
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Breast Cancer Drugs 534
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Breast Cancer Drugs 537
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Breast Cancer Drugs 539
Table 26: New and Unique Target Strategies in Preclinical Development of Breast Cancer Drugs 541
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Breast Cancer Drugs 543
Table 28: Target Strategies of No Data, Suspended or Terminated Breast Cancer Drugs 545
Table 29: Connecting Target Strategy with Its Profile Identification Number 549
Table 30: The Competition Through Close Mechanistic Approximation Among Breast Cancer Drugs 786
Table 31: Overview of Compound Strategy Competition Among Breast Cancer Drugs 79
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |